INT267806

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 4.01
Pain Relevance 1.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Pln) protein complex (Pln)
Pln (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Gabapentin 37 99.36 Very High Very High Very High
Opioid 2 99.12 Very High Very High Very High
agonist 36 98.94 Very High Very High Very High
Dopamine 44 98.76 Very High Very High Very High
sSRI 1 97.40 Very High Very High Very High
tricyclic antidepressant 1 96.58 Very High Very High Very High
headache 1 54.44 Quite High
depression 1 53.08 Quite High
addiction 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Restless Legs Syndrome 683 98.34 Very High Very High Very High
Vomiting 14 84.00 Quite High
Sleep Disorders 140 81.00 Quite High
Disease 14 62.56 Quite High
Renal Disease 21 61.76 Quite High
Fatigue 15 60.20 Quite High
Idiopathic Hypersomnolence 1 57.56 Quite High
Epilepsy 1 55.20 Quite High
Headache 1 54.44 Quite High
Parkinson's Disease 1 54.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Tricyclic antidepressants, selective serotonin reuptake inhibitors and betablockers are considered to exacerbate PLM, whereas dopamine agonists, opioids, gabapentin, apomorphine are considered to reduce PLM (Allen et al., 2004).
Negative_regulation (reduce) of PLM associated with dopamine, agonist, gabapentin, opioid, ssri and tricyclic antidepressant
1) Confidence 0.40 Published 2010 Journal Frontiers in Neuroscience Section Body Doc Link PMC2953451 Disease Relevance 0.86 Pain Relevance 0.67
Ropinirole, compared with placebo, given for 12 weeks was associated with a statistically significant reduction in the PLM-I (from 48.5 to 11.8), in the number of PLMs producing arousal (PLMA-I; from 7.0 to 2.5), and in PLMW-I (from 56.5 to 23.6).
Negative_regulation (reduction) of PLM
2) Confidence 0.08 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671944 Disease Relevance 0.48 Pain Relevance 0.03
In a study of 30 patients, pergolide, in comparison with placebo, was associated with greater total sleep time (mean 373.6 minutes vs 261.9 minutes) and a reduced PLM-I (5.7 vs 55.0) (Wetter et al 1999).
Negative_regulation (reduced) of PLM
3) Confidence 0.08 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671944 Disease Relevance 0.45 Pain Relevance 0.06
In a study of 11 patients, pramipexole, compared with placebo, reduced PLM-I (8.2 vs 35.0) and increased total sleep time (377.6 minutes vs 301.1 minutes) (Saletu et al 2002b).
Negative_regulation (reduced) of PLM
4) Confidence 0.07 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671944 Disease Relevance 0.31 Pain Relevance 0.35
Likewise, in the TREAT RLS US trial, ropinirole, compared with placebo, produced a statistically significant reduction in PLM-I (PLM per hour when supine throughout the night, measured using actigraphy over 3 nights) from 39.8 to 15.6 (Bogan et al 2006).
Negative_regulation (reduction) of PLM associated with restless legs syndrome
5) Confidence 0.07 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671944 Disease Relevance 0.54 Pain Relevance 0.04
In addition, in 16 patients, pergolide produced improvements in sleep efficiency (from 61% to 79%) and reduced PLM-I (from 48.9 to 14.5) (Earley et al 1998).
Negative_regulation (reduced) of PLM
6) Confidence 0.06 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671944 Disease Relevance 0.43 Pain Relevance 0.07
Likewise, in the TREAT RLS US trial, ropinirole, compared with placebo, produced a statistically significant reduction in PLM-I (PLM per hour when supine throughout the night, measured using actigraphy over 3 nights) from 39.8 to 15.6 (Bogan et al 2006).
Negative_regulation (reduction) of PLM associated with restless legs syndrome
7) Confidence 0.05 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671944 Disease Relevance 0.54 Pain Relevance 0.04
Similarly, in 17 patients, pramipexole reduced PLM-I (11.3 vs 73.3 for placebo), and increased total sleep time (374.5 minutes vs 215.4 minutes) and sleep efficiency (77.1% vs 44.5%) (Stiasny-Kolster and Oertel 2004).
Negative_regulation (reduced) of PLM
8) Confidence 0.05 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671944 Disease Relevance 0.39 Pain Relevance 0.38

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox